Constitutive cytokine receptors

The recombinant protein with a modified EPOR transmembrane domain enables constitutive signaling in ACT, addressing the challenge of maintaining cell survival and persistence in low IL-2 environments, thereby enhancing the therapeutic efficacy of adoptive cell therapy.

WO2024261480A1PCT designated stage expired Publication Date: 2024-12-26QUELL THERAPEUTICS LTD
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
PCT/GB2024/051576
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-21
Filing Date
2024-06-20
Publication Date
2024-12-26

AI Technical Summary

Technical Problem

Current adoptive cell therapy (ACT) approaches face challenges in maintaining the survival and persistence of transplanted immune cells, particularly regulatory T cells (Tregs), due to limited availability of interleukin-2 (IL-2) in inflammatory environments and the need for high concentrations of IL-2 during expansion, which can be hindered by immunosuppressive drugs and tissue microenvironment limitations.

Method used

A recombinant protein with a transmembrane domain derived from the erythropoietin receptor (EPOR) that allows constitutive dimerization and signaling in the absence of a ligand, providing a STAT-mediated signal to cells, enhancing their survival and functional persistence.

Benefits of technology

The recombinant protein enables cells to maintain survival and functional persistence in low IL-2 environments, improving the therapeutic efficacy of ACT by providing a consistent pro-survival signal independent of IL-2 availability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000104_0000
    Figure 00000104_0000
  • Figure 00000105_0000
    Figure 00000105_0000
  • Figure 00000106_0000
    Figure 00000106_0000
Patent Text Reader

Abstract

There is provided herein a recombinant protein comprising a transmembrane domain derived from the transmembrane domain of a wildtype erythropoietin receptor (EPOR). Nucleic acid molecules encoding such a recombinant protein, recombinant constructs, vectors and cells containing the nucleic acid molecule, methods of producing such cells, and therapeutic uses thereof are also provided.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Anti-viral vectors

    WO1999041397A1

  • Codon optimisation for expression in retrovirus packaging cells

    WO2001079518A3

  • Polypeptide useful in adoptive cell therapy

    WO2013153391A1

  • FOXP3-expressing car-t regulatory cells

    WO2019241549A1

  • Engineered regulatory t cell

    WO2020044055A1